Current Edition:

Table of Contents

Editor's Note Neil Love, MD

Edith A Perez, MD

Combination versus single-agent chemotherapy for metastatic disease   Assessment of HER2 status   Adjuvant clinical trials of trastuzumab   Use of trastuzumab in metastatic breast cancer   Capecitabine and non-anthracycline regimens for advanced disease References on HER2 testing, trastuzumab and non-anthracycline regimens

Robert W Carlson, MD

The estrogen receptor downregulator, fulvestrant   Fulvestrant versus anastrozole in women with advanced breast cancer   NCCN guidelines for metastatic disease   Nonsteroidal aromatase inhibitors as first-line hormonal therapy   ATAC trial: Implications for adjuvant hormonal therapy References on fulvestrant and aromatase inhibitors

Daniel R Budman, MD

Rationale, development and selection of anti-cancer agents   Capecitabine: A rationally derived drug   Management of capecitabine-associated toxicity   Chemotherapy algorithm for metastatic breast cancer   Adjuvant taxanes for node-negative and node-positive disease References on capecitabine